"She or he can help provide the information needed, like cholesterol levels. “As always, it is important to revisit and discuss these decisions with your health care provider," says Dr. He says the risk factor can be determined by using an American College of Cardiology tool that estimates the risk for atherosclerotic cardiovascular disease. Preventive Services Task Force guidelines suggest aspirin for higher-risk people, those who have a risk of 10 percent or greater over the next 10 years for a fatal or nonfatal heart attack or stroke," says Dr. ![]() ![]() However, there is still evidence a daily low-dose aspirin can reduce the risk of recurrence for someone who has already had a stroke or heart attack. "Since aspirin increases bleeding risk, it should also be avoided by people who have a history of bleeding," adds Dr. "This is not surprising, since it included a population generally at low risk for heart attack or stroke over the next 10 years." The study included more than 19,000 people over 65 in Australia and the U.S. Stephen Kopecky, a Mayo Clinic cardiologist who was not involved with the study. "This study showed that giving aspirin to all patients to try to reduce heart attack was not beneficial," says Dr. “The lessons learned from ADAPTABLE are important and they include gathering already-collected clinical practice data from a huge trial population, partnering with patient advocates, and avoiding open-label problems in the future versions of pragmatic clinical trials,” Jones says.If you're over 70 and don't have a heart attack or stroke history, a study published in the New England Journal of Medicine says baby aspirin isn't necessary for good health. An analysis of the use of a statin or a placebo in helping prevent dementia among patients over 75 has been launched using the aspirin trial model. Investigators are adapting the pragmatic emphasis points in future studies, Jones says. “We noted many reasons for this dose switching, including patient and clinician preferences, and these issues may have introduced bias and complicated the interpretation of results.”īut as a result of ADAPTABLE, new trials are underway. “The big concern was that we discovered a lot of dose switching within the group taking the 325 mg aspirin dose,” Jones says. The study was conducted in an open-label fashion, and the model did present challenges. But the other important element relates to how this study was done and what that means for future studies.” “First, of course, is the aspirin dose recommendation. “There are two big angles to the ADAPTABLE story,” says Jones.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |